Clinical trial NCT05184231: Patient and Physician Survey on Satisfaction With Somatostatin Analogue (SSA) Injections in Acromegaly in China
Official title: Patient and Physician Survey on Satisfaction With Somatostatin Analogue (SSA) Injections in Acromegaly in China
Study type: OBSERVATIONAL
Overall status: WITHDRAWN
Conditions: Acromegaly
Lead sponsor: Ipsen
Sponsor class: INDUSTRY
First posted: 2022-01-11
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Primary care clinic

Brief summary: The purpose of the protocol is to achieve an in-depth understanding of the current satisfaction status of somatostatin analogue (SSA) treatment for acromegaly through patient and physician surveys.


Eligibility criteria: Inclusion Criteria:

For Patients:

* Age 18 years or older
* Diagnosed with acromegaly
* Receiving current SSA injections for acromegaly treatment for at least 3 months
* Signed electronic Informed Consent Form (eICF)

For Physicians:

* Licensed endocrinologists or neurosurgeons
* Having prescribed SSAs for at least five patients with acromegaly in the past 6 months
* Signed eICF

Exclusion Criteria:

* Patients will not be included in the survey if they meet any of the following criteria:
* Patients who are not able to successfully complete the questionnaire independently
* Pregnant patients

Primary outcomes:
measure: Overall patient satisfaction with SSA treatment.
timeFrame: During the whole study period (approximately 3 months).
Secondary outcomes:
measure: Patient satisfaction with symptom control of SSA treatment
timeFrame: During the whole study period (approximately 3 months).
measure: Patient satisfaction with frequency of administration of SSA treatment
timeFrame: During the whole study period (approximately 3 months).
measure: Patient satisfaction with mode of administration of SSA treatment
timeFrame: During the whole study period (approximately 3 months).
measure: Patient satisfaction with convenience of administration of SSA treatment
timeFrame: During the whole study period (approximately 3 months).
measure: Patient satisfaction with injection site reactions of SSA treatment
timeFrame: During the whole study period (approximately 3 months).
measure: Patient satisfaction with adverse reactions to SSA treatment
timeFrame: During the whole study period (approximately 3 months).
measure: Physician overall satisfaction with SSA treatment.
timeFrame: During the whole study period (approximately 3 months).
measure: Physician satisfaction with symptom control of SSA treatment
timeFrame: During the whole study period (approximately 3 months).
measure: Physician satisfaction with frequency of administration of SSA treatment
timeFrame: During the whole study period (approximately 3 months).
measure: Physician satisfaction with mode of administration of SSA treatment
timeFrame: During the whole study period (approximately 3 months).
measure: Physician satisfaction with convenience of administration of SSA treatment
timeFrame: During the whole study period (approximately 3 months).
measure: Physician satisfaction with injection site reactions of SSA treatment
timeFrame: During the whole study period (approximately 3 months).
measure: Physician satisfaction with adverse reactions to SSA treatment
timeFrame: During the whole study period (approximately 3 months).
measure: Aspects of patient concern before initiating SSA treatment
timeFrame: During the whole study period (approximately 3 months).
measure: Aspects of physician concern before prescribing SSA treatment
timeFrame: During the whole study period (approximately 3 months).
measure: Overall patient satisfaction with SSA treatment: satisfied versus dissatisfied with their SSA treatment.
timeFrame: During the whole study period (approximately 3 months).
Other outcomes:
Locations:
Study officials:
References: